Caladrius Biosciences Inc (CLBS):医療機器:M&Aディール及び事業提携情報

◆英語タイトル:Caladrius Biosciences Inc (CLBS) - Medical Equipment - Deals and Alliances Profile
◆商品コード:DATA904C7476
◆発行会社(調査会社):GlobalData
◆発行日:2018年10月
◆ページ数:45
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:医療機器
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Caladrius Biosciences Inc (Caladrius), formerly NeoStem Inc, is a clinical-stage biopharmaceutical company that develops cell therapy products. The company offers multiple technology platforms targeting cardiovascular indications and autoimmune diseases. The company’s lead product CLBS03 is an autologous ex vivo polyclonal T regulatory cell clinical phase 2 therapy used in the treatment of type 1 diabetes mellitus. Its other product candidates include CLBS12 used in the treatment of critical limb ischemia; and CLBS14 used in the treatment of coronary microvascular dysfunction. The company offers T regulatory technology and CD34 technology. Caladrius serves biotechnology, pharmaceutical and medical product companies, and academic research institutions. The company operates in Basking Ridge, Irvine and New York, the US. Caladrius is headquartered in Basking Ridge, New Jersey, the US.

Caladrius Biosciences Inc (CLBS) – Medical Equipment – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Medical eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Caladrius Biosciences Inc, Medical Equipment, Deals By Year, 2012 to YTD 2018 5
Caladrius Biosciences Inc, Medical Equipment Deals By Type, 2012 to YTD 2018 6
Caladrius Biosciences Inc, Medical Equipment, Deals By Region, 2012 to YTD 2018 7
Caladrius Biosciences Inc, Medical Equipment, Deals By Market, 2012 to YTD 2018 8
Caladrius Biosciences Inc, Medical Equipment, Deals Summary, 2012 to YTD 2018 9
Caladrius Biosciences Inc, Medical Equipment, Deal Details 10
Partnerships 10
Caladrius Biosciences Enters into Research Agreement with University of Southern California and California Institute of Technology 10
NeoStem Enters into Co-Development Agreement with Invetech 11
Equity Offering 12
Caladrius Biosciences Plans to Raise up to USD25 Million in Public Offering of Shares 12
Caladrius Biosciences Plans to Raise USD3.8 Million in Private Placement of Shares 13
NeoStem Raises USD29 Million in Public Offering of Shares 14
NeoStem to Raise USD30 Million in Private Placement of Shares 15
NeoStem Completes Public Offering Of Shares For US$40.25 Million 16
NeoStem Files Registration Statement For Private Placement Of Shares For US$8 Million 17
NeoStem Completes Public Offering Of Shares For US$11.5 Million 18
NeoStem Completes Private Placement Of Common Stock For US$3 Million 19
NeoStem Completes Public Offering Of Units For US$6.8 Million 21
Asset Transactions 23
Hitachi Chemical Advanced Therapeutics Solutions Acquires Counter-Flow Centrifugation System from Caladrius Biosciences for USD2.5 Million 23
Acquisition 24
Hitachi Chemical Acquires Remaining 80.1% Interest in Progenitor Cell Therapy from Caladrius Biosciences 24
NeoStem Acquires California Stem Cell 25
Caladrius Biosciences Inc – Key Competitors 27
Caladrius Biosciences Inc – Key Employees 28
Caladrius Biosciences Inc – Locations And Subsidiaries 29
Head Office 29
Other Locations & Subsidiaries 29
Recent Developments 30
Financial Announcements 30
Aug 09, 2018: Caladrius Biosciences reports 2018 second quarter and first six months financial results 30
May 10, 2018: Caladrius Biosciences Reports 2018 First Quarter Financial Results 32
Mar 22, 2018: Caladrius Biosciences Reports 2017 Fourth Quarter and Year End Financial Results 33
Nov 09, 2017: Caladrius Biosciences Reports 2017 Third Quarter Results 35
Aug 10, 2017: Caladrius Biosciences Reports 2017 Second Quarter Results 37
May 15, 2017: Caladrius Biosciences Announces 2017 First Quarter Financial Results 39
Mar 17, 2017: Caladrius Biosciences Announces 2016 Fourth Quarter and Full Year Financial Results 41
Product News 43
Apr 09, 2018: Caladrius Biosciences to Participate at Upcoming April Conferences 43
May 01, 2017: Caladrius Biosciences to Participate at Upcoming May Conferences 44
Appendix 45
Methodology 45
About GlobalData 45
Contact Us 45
Disclaimer 45

List of Tables
Caladrius Biosciences Inc, Medical Equipment, Key Facts, 2017 2
Caladrius Biosciences Inc, Medical Equipment, Deals Summary, 2012 to YTD 2018 2
Caladrius Biosciences Inc, Medical Equipment, Deals By Year, 2012 to YTD 2018 5
Caladrius Biosciences Inc, Medical Equipment Deals By Type, 2012 to YTD 2018 6
Caladrius Biosciences Inc, Medical Equipment, Deals By Region, 2012 to YTD 2018 7
Caladrius Biosciences Inc, Deals By Market, 2012 to YTD 2018 8
Caladrius Biosciences Inc, Medical Equipment, Deals Summary, 2012 to YTD 2018 9
Caladrius Biosciences Enters into Research Agreement with University of Southern California and California Institute of Technology 10
NeoStem Enters into Co-Development Agreement with Invetech 11
Caladrius Biosciences Plans to Raise up to USD25 Million in Public Offering of Shares 12
Caladrius Biosciences Plans to Raise USD3.8 Million in Private Placement of Shares 13
NeoStem Raises USD29 Million in Public Offering of Shares 14
NeoStem to Raise USD30 Million in Private Placement of Shares 15
NeoStem Completes Public Offering Of Shares For US$40.25 Million 16
NeoStem Files Registration Statement For Private Placement Of Shares For US$8 Million 17
NeoStem Completes Public Offering Of Shares For US$11.5 Million 18
NeoStem Completes Private Placement Of Common Stock For US$3 Million 19
NeoStem Completes Public Offering Of Units For US$6.8 Million 21
Hitachi Chemical Advanced Therapeutics Solutions Acquires Counter-Flow Centrifugation System from Caladrius Biosciences for USD2.5 Million 23
Hitachi Chemical Acquires Remaining 80.1% Interest in Progenitor Cell Therapy from Caladrius Biosciences 24
NeoStem Acquires California Stem Cell 25
Caladrius Biosciences Inc, Key Competitors 27
Caladrius Biosciences Inc, Key Employees 28
Caladrius Biosciences Inc, Other Locations 29
Caladrius Biosciences Inc, Subsidiaries 29

List of Figures
Caladrius Biosciences Inc, Medical Equipment, Deals by Type, 2012 to YTD 2018 2
Caladrius Biosciences Inc, Medical Equipment, Deals By Year, 2012 to YTD 2018 2
Caladrius Biosciences Inc, Medical Equipment, Deals By Region, 2012 to YTD 2018 2
Caladrius Biosciences Inc, Medical Equipment, Deals By Market, 2012 to YTD 2018 2
Caladrius Biosciences Inc, Medical Equipment, Deals By Year, 2012 to YTD 2018 5
Caladrius Biosciences Inc, Medical Equipment, Deals by Type, 2012 to YTD 2018 6
Caladrius Biosciences Inc, Medical Equipment, Deals By Region, 2012 to YTD 2018 7
Caladrius Biosciences Inc, Medical Equipment, Deals by Market, 2012 to YTD 2018 8

★海外企業調査レポート[Caladrius Biosciences Inc (CLBS):医療機器:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Cosmo Pharmaceuticals NV (COPN)-医療機器分野:企業M&A・提携分析
    Summary Cosmo Pharmaceuticals NV (Cosmo) is a pharmaceutical company that develops drugs for the treatment of gastro-intestinal diseases. The company develops its pharmaceutical products based on its multi matrix (MMX) technology. Its proprietary clinical development pipeline intended for the treatm …
  • Penumbra Inc (PEN):企業の財務・戦略的SWOT分析
    Penumbra Inc (PEN) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and th …
  • Dechra Pharmaceuticals Plc (DPH):企業の財務・戦略的SWOT分析
    Summary Dechra Pharmaceuticals Plc (Dechra) is a manufacturer and distributor of veterinary pharmaceutical products. The company's product portfolio includes vetoryl, felimazole, thyforon, malaseb, canaural, isaderm, cardisure, comfortan, soludox, methoxasol, cyclospray and octacillin, among others. …
  • China Gezhouba Group Co Ltd (600068):企業の財務・戦略的SWOT分析
    China Gezhouba Group Co Ltd (600068) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and …
  • Seguradoras Unidas, S.A.:企業の戦略・SWOT・財務分析
    Seguradoras Unidas, S.A. - Strategy, SWOT and Corporate Finance Report Summary Seguradoras Unidas, S.A. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service o …
  • Specialised Therapeutics Australia Pty Ltd-製薬・医療分野:企業M&A・提携分析
    Summary Specialised Therapeutics Australia Pty Ltd (STA) is a biopharmaceutical company that develops and commercializes therapies and technologies for unmet medical needs. The company’s product portfolio includes abraxane, gliolan, oncotype dx, iclusig, oncotype dx prostate and aloxi. Its pipeline …
  • Advaxis Inc (ADXS):製薬・医療:M&Aディール及び事業提携情報
    Summary Advaxis Inc (Advaxis) is a biotechnology company that focuses on the discovery, development and commercialization of multiple cancer immunotherapies. The company develops immunotherapies based on its proprietary Lm Technology that uses bioengineered live attenuated Listeria monocytogenes (Lm …
  • Muscatine Power and Water:企業の発電所・SWOT分析2018
    Muscatine Power and Water - Power Plants and SWOT Analysis, 2018 Update Summary The report contains a detailed description of the power generation company’s business operations, history, corporate strategy, and business structure. This report contains a detailed SWOT analysis, information on key emp …
  • Edion Corporation (2730):企業の財務・戦略的SWOT分析
    Edion Corporation (2730) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses …
  • Genocea Biosciences Inc (GNCA):企業の財務・戦略的SWOT分析
    Summary Genocea Biosciences Inc (Genocea), formerly Genocea Inc, is a cancer vaccines provider. The company discovers and develops T cell-directed vaccines and immunotherapies to treat infectious diseases and cancer. It provides Gen-009 and Gen-010 neoantigen cancer Vaccine pipeline.Genoceaatlas tec …
  • Flowserve Corporation:企業の戦略・SWOT・財務情報
    Flowserve Corporation - Strategy, SWOT and Corporate Finance Report Summary Flowserve Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerin …
  • Jiangsu Jiuding New Material Co Ltd (002201):企業の戦略的SWOT分析
    Jiangsu Jiuding New Material Co Ltd (002201) - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors …
  • Kamada Ltd (KMDA):企業の財務・戦略的SWOT分析
    Kamada Ltd (KMDA) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the …
  • Karambunai Corporation Berhad:企業の戦略・SWOT・財務分析
    Karambunai Corporation Berhad - Strategy, SWOT and Corporate Finance Report Summary Karambunai Corporation Berhad - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and …
  • Varex Imaging Corp (VREX):企業の財務・戦略的SWOT分析
    Varex Imaging Corp (VREX) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses …
  • Rad Source Technologies Inc:企業の戦略的SWOT分析
    Rad Source Technologies Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major product …
  • L’Oreal USA Inc:企業の戦略的SWOT分析
    L'Oreal USA Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and servic …
  • PTT Exploration and Production Public Company Limited:企業の戦略・SWOT・財務分析
    PTT Exploration and Production Public Company Limited - Strategy, SWOT and Corporate Finance Report Summary PTT Exploration and Production Public Company Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's …
  • Emeco Holdings Ltd:企業の戦略・SWOT・財務情報
    Emeco Holdings Ltd - Strategy, SWOT and Corporate Finance Report Summary Emeco Holdings Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and …
  • The Tata Power Co Ltd (TATAPOWER):企業の財務・戦略的SWOT分析
    The Tata Power Co Ltd (TATAPOWER) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and we …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆